Published in the New England Journal of Medicine Catalyst
In a new study, published in the New England Journal of Medicine Catalyst, participants using Twin Health lowered their A1C below diabetes range while reducing glucose-lowering medications.
Our AI digital twin™ technology pairs with a human clinical care team to deliver hyper-individualized care at scale. This approach has a proven impact on the root causes of chronic metabolic disease.
Learn Morepublished in the New England Journal of Medicine Catalyst, our AI digital twin™ approach achieved results that redefine what’s possible in type 2 diabetes care.
85%
GLP-1 elimination
96%
SGLT-2 elimination
46%
insulin elimination
Twin Health’s sustained results have been validated in multiple peer-reviewed publications.
normalized blood pressure
The Journals of American College of Cardiology
Improvement in A1C
The American Association of Clinical Endocrinology
lost ≥5% of their body weight within a year
Endocrine Society
Twin Health’s AI digital twin™ technology is a powerful, non-pharmacological approach to improving and preventing chronic metabolic diseases, including type 2 diabetes, prediabetes, and obesity, while substantially reducing healthcare costs.
We combine precision medicine, advanced AI insights, and a dedicated clinical care team to create custom, dynamic health plans for each member — targeting nutrition, medications, sleep, movement, and stress.
Our hyper-individualized approach helps members not only achieve but sustain optimal health outcomes.
88% of Digital Twin participants in the Cleveland Clinic study stayed engaged for a full year, driving long-term behavior change and health improvements.
Year 1 results already show sustained outcomes, and Year 2 findings will further demonstrate our long-term outcomes at scale.
Twin Health can dramatically improve primary care for metabolic health — helping members improve their lives while reducing reliance on high-cost traditional treatments.
Request A Meeting
